HRP20211762T1 - Derivati benzoksaborola za liječenje bakterijskih infekcija - Google Patents

Derivati benzoksaborola za liječenje bakterijskih infekcija Download PDF

Info

Publication number
HRP20211762T1
HRP20211762T1 HRP20211762TT HRP20211762T HRP20211762T1 HR P20211762 T1 HRP20211762 T1 HR P20211762T1 HR P20211762T T HRP20211762T T HR P20211762TT HR P20211762 T HRP20211762 T HR P20211762T HR P20211762 T1 HRP20211762 T1 HR P20211762T1
Authority
HR
Croatia
Prior art keywords
solvate
hydrate
salt
compound according
pharmaceutically acceptable
Prior art date
Application number
HRP20211762TT
Other languages
English (en)
Inventor
Vincent S. Hernandez
Charles Ding
Jacob J. Plattner
Michael Richard Kevin Alley
Fernando Rock
Suoming Zhang
Eric Easom
Xianfeng Li
Ding Zhou
Original Assignee
Anacor Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals, Inc. filed Critical Anacor Pharmaceuticals, Inc.
Publication of HRP20211762T1 publication Critical patent/HRP20211762T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Spoj koji ima strukturu koja je: [image] u kojoj R4 je izabran iz grupe koja se sastoji od sljedećih: halogen, metil, etil, propil, izopropil, butil, izobutil, sek-butil, metoksi, etoksi, propoksi, izopropoksi, butoksi, izobutoksi i sek-butoksi; i gdje a je 2, 3 ili 4; i R12 je izabran iz grupe koja se sastoji od sljedećih: H, OH, NH2, metil, etil, - NHS(O)2CH3, cijano, -NHC(O)CH3, -NHC(O)NHCH2CH3, -C(O)NH2, -C(O)OH, 4-(metoksi)fenil, benzil, benzoksi, -NHC(O)OCH2Ph, -C(O)NHCH2CH2OH i -C(NH2)(NH); ili njegova sol, hidrat ili solvat.
2. Spoj prema zahtjevu 1 ili njegova sol, hidrat ili solvat, koji ima strukturu koja je: [image] u kojoj C* je stereocentar atoma ugljika koji ima konfiguraciju koja je (R) ili (S).;
3. Spoj prema zahtjevu 2 ili njegova sol, hidrat ili solvat, naznačeno time što C* stereocentar je u (S) konfiguraciji.
4. Spoj prema zahtjevu 1 ili njegova sol, hidrat ili solvat, naznačeno time što R4 je izabran iz grupe koja se sastoji od fluora, klora, broma i joda.
5. Spoj prema zahtjevu 4 ili njegova sol, hidrat ili solvat, naznačeno time što R4 je klor.
6. Spoj prema zahtjevu 1 do 3 ili njegova sol, hidrat ili solvat, naznačeno time što R4 je izabran iz grupe koja se sastoji od sljedećih: metil, etil, propil, izopropil, butil, izobutil, sek-butil.
7. Spoj prema zahtjevu 6 ili njegova sol, hidrat ili solvat, naznačeno time što R4 je metil.
8. Spoj prema bilo kojem od zahtjeva 1 do 6 ili njegova sol, hidrat ili solvat, naznačeno time što a je 2.
9. Spoj prema bilo kojem od zahtjeva 1 do 6 ili njegova sol, hidrat ili solvat, naznačeno time što R12 je OH.
10. Kompozicija koja sadrži: a) prvi stereoizomer spoja prema bilo kojem od zahtjeva 2 do 9 ili njegovu sol, hidrat ili solvat; b) najmanje jedan dodatni stereoizomer prvog stereoizomera; pri čemu je prvi stereoizomer prisutan u enantiomernom višku od najmanje 80% u odnosu na navedeni najmanje jedan dodatni stereoizomer.
11. Kombinacija koja sadrži spoj prema bilo kojem od zahtjeva 1 do 9 ili njegovu farmaceutski prihvatljivu sol, zajedno sa najmanje jednim drugim terapeutski aktivnim sredstvom.
12. Farmaceutska formulacija koja sadrži: a) spoj prema bilo kojem od zahtjeva 1 do 9 ili njegovu farmaceutski prihvatljivu sol; i b) farmaceutski prihvatljiv ekscipijent.
13. Spoj ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat, kako je definirano u bilo kojem od zahtjeva 1 do 9, za uporabu u terapiji.
14. Spoj ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat, kako je definirano u bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju bolesti izazvane infekcijom mikobakterijom.
15. Spoj ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat, kako je definirano u bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju tuberkuloze.
HRP20211762TT 2010-09-07 2011-09-07 Derivati benzoksaborola za liječenje bakterijskih infekcija HRP20211762T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38059610P 2010-09-07 2010-09-07
EP17176654.6A EP3251678B1 (en) 2010-09-07 2011-09-07 Benzoxaborole derivatives for treating bacterial infections

Publications (1)

Publication Number Publication Date
HRP20211762T1 true HRP20211762T1 (hr) 2022-02-18

Family

ID=44653589

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211762TT HRP20211762T1 (hr) 2010-09-07 2011-09-07 Derivati benzoksaborola za liječenje bakterijskih infekcija

Country Status (25)

Country Link
US (4) US8703742B2 (hr)
EP (2) EP3251678B1 (hr)
JP (4) JP5952280B2 (hr)
KR (2) KR102152901B1 (hr)
CN (2) CN108610356B (hr)
AU (1) AU2011299243C1 (hr)
BR (1) BR112013005426B1 (hr)
CA (1) CA2810021C (hr)
CY (1) CY1124728T1 (hr)
DK (2) DK3251678T3 (hr)
EA (2) EA033311B1 (hr)
ES (2) ES2635333T3 (hr)
HK (1) HK1247841A1 (hr)
HR (1) HRP20211762T1 (hr)
HU (1) HUE059033T2 (hr)
IL (2) IL225000A (hr)
LT (1) LT3251678T (hr)
MX (1) MX338209B (hr)
PL (1) PL3251678T3 (hr)
PT (1) PT3251678T (hr)
RS (1) RS62548B1 (hr)
SG (2) SG187969A1 (hr)
SI (1) SI3251678T1 (hr)
WO (1) WO2012033858A2 (hr)
ZA (1) ZA201301598B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008131324A (ru) 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
US9440994B2 (en) * 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN108610356B (zh) * 2010-09-07 2021-02-26 阿纳科制药公司 苯并氧杂硼杂环戊二烯衍生物用于治疗细菌感染
JP6031122B2 (ja) * 2011-12-22 2016-11-24 ミクウルク ファーマシューティカルズ,インコーポレイテッド 抗微生物療法のための三環式ホウ素化合物
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CN105101791B (zh) 2013-01-30 2017-11-17 美国陶氏益农公司 苯硼酸半酯作为挥发性抗微生物剂在肉类、植物或植物部分上的用途
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
AP2015008638A0 (en) 2013-02-01 2015-08-31 Anacor Pharmaceuticals Inc Boron-containing small molecules as antiprotozoal agents
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
HRP20220384T1 (hr) * 2013-08-09 2022-07-22 Glaxosmithkline Intellectual Property (No. 2) Limited Triciklički benzoksaborol spojevi i njihove uporabe
EA038093B1 (ru) * 2013-12-20 2021-07-05 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Способ лечения заболевания, вызванного инфекцией комплекса mycobacterium tuberculosis, с использованием (s)-(3-хлор-7,8-дигидро-2h-1,6,9-триокса-9a-борабензо[cd]азулен-2-ил)метанамина или его фармацевтически приемлемой соли
CA2953881A1 (en) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Tricyclic benzoxaboroles as antibacterial agents
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
EP3609504A4 (en) 2017-03-01 2021-03-03 Anacor Pharmaceuticals, Inc. NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
CN111655035A (zh) 2017-11-30 2020-09-11 博瑞金股份有限公司 苯并氧杂硼杂环戊烯化合物和其制剂
CN108727176B (zh) * 2018-07-26 2021-05-18 荆楚理工学院 一种制备5-卤-2,3-二羟基苯甲醛的方法
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
US20220275007A1 (en) * 2019-07-30 2022-09-01 Boragen, Inc. Flow reaction process for manufacture of boron-containing agrochemicals
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
WO2022043936A1 (en) 2020-08-31 2022-03-03 Pfizer Inc. Methods of protecting rna
EP4384527A1 (en) * 2022-06-23 2024-06-19 Micurx Pharmaceuticals, Inc. Prodrugs of boron compounds and their use in treating bacterial infections
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5274792A (en) 1989-08-19 1993-12-28 Fujitsu Limited Information processing apparatus with parallel instruction decoding
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
AU4486097A (en) 1996-09-19 1998-04-14 Board Of Trustees Of The Leland Stanford Junior University Dna adenine methyltransferases and uses thereof
DE69730737D1 (de) 1996-12-02 2004-10-21 Chisso Corp Optisch aktive nitroalkohol-derivate, optisch aktive aminoalkohol-derivate und verfahren zu ihrer herstellung
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
KR20010086005A (ko) 1998-11-06 2001-09-07 스타르크, 카르크 트리사이클릭 피라졸 유도체
WO2000044387A1 (fr) 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
JP2003501431A (ja) 1999-05-25 2003-01-14 ザ ペン ステート リサーチ ファウンデイション Dnaメチル基転移酵素阻害剤
WO2001014578A1 (en) 1999-08-25 2001-03-01 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2001049302A1 (en) 2000-01-06 2001-07-12 Marantech Holding, Llc Compositions and methods for facilitating skin growth and managing skin conditions
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
AU2001275930B2 (en) 2000-07-14 2007-05-10 Eisai Inc. Alpha-msh related compounds and methods of use
DE60124759T2 (de) 2000-11-30 2007-03-15 The Penn State Research Foundation Dna methyl transferase inhibitoren
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
EP1444981A1 (en) 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
CN1325504C (zh) 2002-01-10 2007-07-11 宾夕法尼亚州研究基金会 制备二芳基硼酸烷基酯和络合的二芳基硼酸的方法
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
CN100384791C (zh) 2002-12-02 2008-04-30 索尔维亚斯股份公司 碳-杂原子双键的催化氢化
WO2004056322A2 (en) 2002-12-18 2004-07-08 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
WO2005000200A2 (en) 2003-05-09 2005-01-06 Sugen, Inc. Novel kinases
US7465836B2 (en) 2003-06-16 2008-12-16 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
ES2464444T3 (es) 2004-05-12 2014-06-02 The Brigham And Women's Hospital, Inc. Gelsolina para uso en el tratamiento de infecciones
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
EP1853251B1 (en) 2005-02-16 2013-04-24 Anacor Pharmaceuticals, Inc. Halogen-substituted boronophthalides for the treatment of infections
EP1856113B1 (en) 2005-03-08 2016-01-06 Agency for Science, Technology and Research Chiral bisoxazoline catalysts
US20060222671A1 (en) 2005-03-30 2006-10-05 Astion Development A/S Dermatological compositions and salts for the treatment of dermatological diseases
WO2007022437A2 (en) 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
RU2008131324A (ru) 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
HUE044941T2 (hu) * 2006-02-16 2019-11-28 Anacor Pharmaceuticals Inc Bórtartalmú kismolekulák mint gyulladásgátló szerek
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP2044091A4 (en) 2006-06-12 2010-08-04 Anacor Pharmaceuticals Inc COMPOUNDS FOR TREATING A PERIODONTAL DISEASE
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR20150065941A (ko) 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
EP2285384A4 (en) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
SG172040A1 (en) 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
CN108610356B (zh) * 2010-09-07 2021-02-26 阿纳科制药公司 苯并氧杂硼杂环戊二烯衍生物用于治疗细菌感染

Also Published As

Publication number Publication date
JP2016199558A (ja) 2016-12-01
ES2635333T3 (es) 2017-10-03
AU2011299243A1 (en) 2013-03-28
RS62548B1 (sr) 2021-12-31
MX338209B (es) 2016-04-07
KR101949423B1 (ko) 2019-02-18
US20140315860A1 (en) 2014-10-23
CN108610356A (zh) 2018-10-02
CA2810021C (en) 2018-05-29
BR112013005426B1 (pt) 2021-08-24
IL225000A (en) 2016-03-31
CN108610356B (zh) 2021-02-26
DK3251678T3 (da) 2021-11-22
AU2011299243C1 (en) 2016-06-02
JP2018058836A (ja) 2018-04-12
LT3251678T (lt) 2021-12-10
JP5952280B2 (ja) 2016-07-13
PT3251678T (pt) 2021-11-22
US9751898B2 (en) 2017-09-05
KR102152901B1 (ko) 2020-09-07
DK2613788T3 (en) 2017-08-07
ES2898695T3 (es) 2022-03-08
WO2012033858A3 (en) 2012-05-10
AU2011299243B2 (en) 2015-09-17
EA201791850A1 (ru) 2018-01-31
ZA201301598B (en) 2021-08-25
EP3251678A1 (en) 2017-12-06
MX2013002651A (es) 2013-04-19
EP3251678B1 (en) 2021-10-20
HK1247841A1 (zh) 2018-10-05
US20170355719A1 (en) 2017-12-14
EA033311B1 (ru) 2019-09-30
US20190345173A1 (en) 2019-11-14
US20120115813A1 (en) 2012-05-10
BR112013005426A2 (pt) 2016-06-07
IL244556B (en) 2020-07-30
CY1124728T1 (el) 2022-07-22
US11008345B2 (en) 2021-05-18
IL244556A0 (en) 2016-04-21
PL3251678T3 (pl) 2022-01-10
SG187969A1 (en) 2013-04-30
WO2012033858A2 (en) 2012-03-15
SI3251678T1 (sl) 2022-01-31
EP2613788A2 (en) 2013-07-17
ES2898695T8 (es) 2022-03-16
EA201390274A1 (ru) 2013-08-30
JP2013541514A (ja) 2013-11-14
JP2019112431A (ja) 2019-07-11
EA028743B1 (ru) 2017-12-29
KR20190018549A (ko) 2019-02-22
SG10201507032YA (en) 2015-10-29
CA2810021A1 (en) 2012-03-15
CN103140228A (zh) 2013-06-05
JP6491294B2 (ja) 2019-03-27
HUE059033T2 (hu) 2022-10-28
KR20140093598A (ko) 2014-07-28
EP2613788B1 (en) 2017-06-21
US8703742B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20151000T1 (hr) Antivirusni spojevi
HRP20171512T1 (hr) Derivati betulina
RS54258B1 (en) SRC / ABL INHIBITOR FORMULATIONS
JP2013541514A5 (hr)
JP2013528600A5 (hr)
HRP20210942T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20090077A2 (hr) Modulatori farmakokinetičkih svojstava terapeutika
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
EA200970535A1 (ru) Антибактериальные производные хинолина
JP2011527299A5 (hr)
JP2011507896A5 (hr)
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
EA200970534A1 (ru) Антибактериальные производные хинолина
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
MX2012006297A (es) Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih.
WO2008143649A3 (en) Novel oxazolidinone compounds as antiinfective agents
RU2011111117A (ru) Лечение аутоиммунных заболеваний
EA201070018A1 (ru) Замещенные 2-[2-(фенил)этиламино] алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов
JP2012508256A5 (hr)
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения